Schizophrenia
2,921
189
228
2,027
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
672 trials with published results (23%)
Research Maturity
2027 completed trials (69% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
7.3%
212 terminated out of 2921 trials
90.5%
+4.0% vs benchmark
27%
791 trials in Phase 3/4
33%
672 of 2027 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2027 completed trials
Clinical Trials (2921)
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia
Effects of Noninvasive Brain Stimulation Techniques on BDNF Levels
Efficiency Assessment of BREFORM. A Multicentric Stepped-wedge Randomized Control Trial.
French Source-monitoring Task
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
A Computational Neuroscience Perspective on the Shared Social Cognitive Deficits of Autism and Schizophrenia
Studies of Frontal Lobe Brain Functioning in Schizophrenia
PET Scanning in Parkinson s Disease
Mental Health During the Whole Life Cycle of Community Patients With Schizophrenia
SUCCEED Africa: Support, Comprehensive Care and Empowerment of People With Psychosocial Disabilities
Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers
An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia
Cue-based Intervention in Prospective Memory and Medication Adherence.
Feasibility and Acceptability of Mobile Mental Health App for SZ and SZA
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia